AI Article Synopsis
- A study was conducted to clarify the conflicting results about how intracerebroventricular (icv) treatment with Growth Hormone-Releasing Factor (GRF) affects Growth Hormone (GH) secretion.
- The icv injection of rat GRF stimulated GH release in live rats, while the hpGRF peptide suppressed GH secretion instead.
- Further analysis revealed that the hpGRF-44-NH2 peptide was mainly ovine Corticotropin-Releasing Factor (oCRF) with a small proportion of human GRF, indicating that the observed effects were primarily due to the oCRF and not the hpGRF.
Article Abstract
The existence of discordant results regarding the effects of intracerebroventricular (icv) administration of GRF on GH secretion prompted a reexamination of the central actions of GRF and a detailed chemical characterization of the peptide designated as hpGRF-44-NH2. The icv injection of 10 micrograms rat (r) GRF to freely-moving rats caused an acute stimulation of GH release, whereas 10 micrograms of the putative hpGRF peptide icv continued to suppress spontaneous GH secretion. Through a series of biochemical and immunologic studies we demonstrate that peptide hpGRF-44-NH2, code number 92-81-5G-41-47, is predominantly ovine (o) CRF and also contains a small amount (3-5%) human (h) GRF-44-NH2. We conclude that the major effect of icv administered GRF, at high doses, is to stimulate GH release and that the central actions previously attributed to the hpGRF peptide are, in fact, due to the oCRF component of this compound.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1210/endo-118-3-1246 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!